Xencor Inc (XNCR) is a biotechnology company that specializes in the development of engineered monoclonal antibodies for the treatment of various diseases. Technical analysis is an important tool used by traders and investors to make decisions about buying or selling a particular stock. By analyzing historical price and volume data, as well as various technical indicators, traders can gain insight into the future direction of a stock's price.

There are several technical indicators that can be used to analyze the Xencor Inc (XNCR) stock. The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. A high RSI value indicates an overbought condition, while a low RSI value indicates an oversold condition. Traders can use the RSI to identify potential buying or selling opportunities.

Xencor  (XNCR) Technical Analysis

Technical analysis indicators for Xencor Inc (XNCR) stock include RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. This analysis provides insights into the stock's performance and potential trends. Learn more about XNCR's technical analysis here.

Xencor Inc (XNCR) Technical Analysis Indicators

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

Xencor 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	68.83	Neutral	46.8%
auto_graphMACD	8.88	Neutral	1.4%
auto_graphCCI	105.62	Sell	144.8%
auto_graphADX	41.07	Neutral	-
auto_graphATR	8.87	Buy	-
auto_graphWILLR	-2.86	Sell	110.0%
auto_graphROC	79.66	Neutral	-23.1%
auto_graphSTOCHRSI	23.03	Neutral	35.1%

Buy	1	-87.50%
Hold	5	-37.50%
Sell	2	-75.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Xencor (XNCR) Technical Analysis

Keep an eye on Xencor

Frequently Asked Questions

What are the technical signals for Xencor (XNCR) stock based on the last 30 days?

Take Your Investments to a Whole New Level